PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a malaria drug help fight tough skin cancer?
Disease control TerminatedThis study tested whether adding the drug hydroxychloroquine to the standard two-drug treatment (dabrafenib and trametinib) could better control advanced melanoma that has a specific genetic change (BRAF V600E/K). It aimed to see if the three-drug combo could delay cancer growth …
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Drug combo tested to shrink tumors before melanoma surgery
Disease control TerminatedThis study tested whether giving two targeted drugs (encorafenib and binimetinib) before surgery could help shrink melanoma tumors in patients whose cancer had spread to nearby lymph nodes. The drugs work by blocking specific signals that help cancer cells grow. The trial also ex…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug combo tested for Tough-to-Treat advanced cancers
Disease control TerminatedThis early-phase study tested the safety and effectiveness of adding a new drug called plinabulin to a combination of radiation and immunotherapy. It was for patients with advanced cancers (like lung, bladder, and melanoma) that had continued to grow despite prior immunotherapy. …
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Doctors test engineered virus to attack deadly skin cancer
Disease control TerminatedThis early-phase study tested a genetically modified virus designed to kill melanoma cancer cells. The virus was injected directly into tumors and given intravenously to patients with advanced melanoma that had stopped responding to standard treatments. The main goals were to fin…
Matched conditions: PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC